References and Notes
1
Garner RC.
Mutat. Res.
1998,
402:
67
2
Neumann HG.
J. Cancer Res. Clin. Oncol.
1986,
112:
100
3
Beland FA.
Kadlubar FF.
Environ. Health Perspect.
1985,
62:
19
4a
Guengerich FP.
Drug Metab. Rev.
2002,
34:
607
4b
Meier C.
Boche G.
Chem. Ber.
1990,
123:
1691
4c
Famulok M.
Boche G.
Angew. Chem., Int. Ed. Engl.
1989,
28:
468 ; Angew. Chem. 1989, 101, 470
5
Tureky RJ.
Rossi SC.
Welti DH.
Lay JO.
Kadlubar FF.
Chem. Res. Toxicol.
1992,
5:
479
6
Tureky RJ.
Markovic J.
Chem. Res. Toxicol.
1994,
7:
752
7
Meier C.
Gräsl S.
Detmer I.
Marx A.
Nucleosides, Nucleotides Nucleic Acids
2005,
24:
691
8a
Abuaf P.
Hingerty BE.
Broyde S.
Grunberger D.
Chem. Res. Toxicol.
1995,
8:
369
8b
Shibutani S.
Suzuki N.
Grollman AP.
Biochemistry
1998,
37:
12034
8c
Shibutani S.
Fernandes A.
Suzuki N.
Zhou L.
Johnson F.
Grollman AP.
J. Biol. Chem.
1999,
274:
27433
9
Lakshman MK.
Hilmer JH.
Martin JQ.
Keeler JC.
Dinh YQV.
Ngassa FN.
Russon LM.
J. Am. Chem. Soc.
2001,
123:
7779
10a
De Riccardis F.
Bonala RR.
Johnson F.
J. Am. Chem. Soc.
1999,
121:
10453
10b
De Riccardis F.
Johnson F.
Org. Lett.
2000,
2:
293
11
Schoffers E.
Olsen PD.
Means JC.
Org. Lett.
2001,
3:
4221
12
Meier C.
Gräsl S.
Synlett
2002,
802
13
Guy A.
Duplaa A.-M.
Harel P.
Téoule R.
Helv. Chim. Acta
1988,
71:
1566
14
Markiewicz WT.
Samek J.
Smrt J.
Tetrahedron Lett.
1980,
21:
4523
15
N
6-Benzoyl-8-N-(4-methoxyphenylamino)-3′,5′-O-[1,1,3,3-tetrakis(isopropyl)-1,3-disiloxanediyl]-2′-deoxyadenosine (7a) and N
6-benzoyl-8-N-(4-aminobiphenyl)-3′,5′-O-[1,1,3,3-tetrakis(isopropyl)-1,3-disiloxanediyl]-2′-deoxy-adenosine (7b): N
6-Bz-8-bromo-3′,5′-O-(TIPDS)-2′-dA 6 (500 mg, 0.87 mmol), Cs2CO3 (426 mg, 1.31 mmol), tris(di-benzylideneacetone)dipalladium(0) [Pd2(dba)3; 80.0 mg, 87.0 µmol], racemic-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP; 163 mg, 0.26 mmol) and p-anisidine (4c; 215 mg, 1.74 mmol) or 4-aminobiphenyl (4b; 295 mg, 1.74 mmol) were solubilized in anhyd 1,2-dimethoxyethane (30 mL) in an inert gas atmosphere and stirred at 90 °C until the reaction was complete (TLC analysis). After cooling to r.t., sat. NaHCO3 solution (1 mL) was added. After addition of brine (10 mL) the layers were separated and the aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (3 × 10 mL) and once with a mixture of brine (10 mL) and H2O (2 mL). The organic layer was dried (Na2SO4) and the solvent was removed in vacuo. Purification by chromatography on silica gel, eluting with 20% EtOAc in hexane afforded 7a (374 mg, 0.61 mmol; 70%) and 7b (345 mg, 0.52 mmol; 60%) as light-yellow foams.
16
7a: 1H NMR (400 MHz, CDCl3): δ = 8.16 (s, 1 H), 7.48 (m, 2 H), 7.41 (br s, 1 H), 6.88 (m, 2 H), 6.31 (dd, J = 3.8, 7.8 Hz, 1 H), 5.34 (br s, 2 H), 4.90 (dd, J = 7.9, 15.2 Hz, 1 H), 4.16 (dd, J = 3.4, 9.2 Hz, 1 H), 3.98 (dd, J = 5.0, 12.5 Hz, 1 H), 3.90 (ddd, J = 3.4, 4.9, 7.0 Hz, 1 H), 3.79 (s, 3 H), 3.06 (ddd, J = 3.6, 8.1, 13.4 Hz, 1 H), 2.59 (ddd, J = 7.9, 13.4 Hz, 1 H), 0.89-1.13 (m, 28 H). 13C NMR (101 MHz, CDCl3): δ = 155.8, 152.5, 149.4, 132.5, 121.5, 117.4, 114.5, 85.3, 83.8, 70.5, 61.9, 55.7, 38.8, 17.0-17.6, 12.6-13.5. HRMS (FAB): m/z [M + H]+ calcd for C29H46N6O5Si2: 615.3147; found: 615.3155. 7b: 1H NMR (400 MHz, CDCl3): δ = 8.19 (s, 1 H), 7.78 (br s, 1 H), 7.69 (m, 2 H), 7.58 (m, 4 H), 7.44 (m, 2 H), 7.33 (m, 1 H), 6.35 (dd, J = 3.8, 7.5 Hz, 1 H), 5.59 (s, 2 H), 4.88 (dd, J = 7.9, 15.2 Hz, 1 H), 4.16 (dd, J = 3.6, 12.6 Hz, 1 H), 4.04 (dd, J = 4.8, 12.5 Hz, 1 H), 3.95 (ddd, J = 3.0, 4.4, 7.3 Hz, 1 H), 3.07 (ddd, J = 3.6, 8.0, 13.4 Hz), 2.59 (ddd, J = 7.8, 13.4 Hz, 1 H), 0.91-1.12 (m, 28 H). 13C NMR (101 MHz, CDCl3): δ = 156.7, 152.4, 149.7, 148.3, 140.9, 132.5, 121.5, 117.4, 114.5, 85.3, 83.8, 70.5, 61.9, 55.7, 38.8, 17.0-17.6, 12.6-13.5. HRMS (FAB): m/z [M + H]+ calcd for C34H48N6O4Si2: 661.3354; found: 661.3377.
17
N
6-Benzoyl-8-N-(4-methoxyphenylamino)-5′-O-dimeth-oxytrityl-2′-deoxyadenosine-3′-yl-β-cyanoethyl-N,N′-diisopropylphosphoramidite (10a) and N
6-benzoyl-8-N-(4-aminobiphenyl)-5′-O-dimethoxytrityl-2′-deoxy-adenosine-3′-yl-β-cyanoethyl-N,N′-diisopropylphosphor-amidite (10b): N
6-Bz-8-N-(4-methoxyphenylamino)-5′-O-DMTr-2′-dA (150 mg, 0.19 mmol) and N
6-Bz-8-N-(4-aminobi-phenyl)-5′-O-DMTr-2′-dA (150 mg, 0.18 mmol), respec-tively, were dissolved in anhydrous CH2Cl2 (3 mL) and anhydrous MeCN (3 mL) in an inert gas atmosphere and treated subsequently with a solution of 4,5-dicyano-imidazole in MeCN (0.25 M, 1.5 mL, 0.38 mmol) and 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphordiamidite (86 mg, 0.29 mmol). After stirring for 30 min at r.t., the reaction was stopped by adding of MeOH (0.5 mL). The solution was diluted with CH2Cl2 (50 mL) and washed with 5% aq NaHCO3 followed by brine. The organic layer was dried and concentrated to dryness. The residue was purified by chromatography on silica gel, eluting with CH2Cl2, 2% Et3N and 0-3% MeOH. The products were redissolved in CH2Cl2 and further washed with H2O to give 10a (130 mg, 0.13 mmol; 69%) and 10b (116 mg, 0.11 mmol; 62%) as light-yellow solids.
18
9a: 2 diastereomers + 2 rotamers. 1H NMR (400 MHz, C6D6): δ = 9.55 (m, 2 H), 9.18 (s, 1 H), 9.16 (s, 1 H), 8.90 (m, 2 H), 8.67 (s, 1 H), 8.66 (s, 1 H), 8.29 (s, 1 H), 8.27 (s, 1 H), 7.91 (m, 2 H), 7.82 (m, 5 H), 7.75 (m, 3 H), 7.64-7.70 (m, 4 H), 7.54-7.62 (m, 6 H), 7.43-7.53 (m, 8 H), 7.32 (m, 12 H), 7.32 (m, 5 H), 7.08-7.16 (m, 8 H), 6.87-7.06 (m, 22 H), 6.64-6.80 (m, 24 H), 5.99-6.13 (m, 2 H), 5.91 (m, 2 H), 5.25 (m, 2 H), 5.07 (m, 4 H), 4.50-4.64 (m, 2 H), 4.41 (m, 2 H), 3.81-3.93 (m, 4 H), 3.61-3.75 (m, 4 H), 3.44-3.62 (m, 16 H), 3.22-3.43 (m, 36 H), 2.28-2.53 (m, 4 H), 1.68-2.00 (m, 12 H), 1.11-1.23 (m, 48 H). 13C NMR (101 MHz, C6D6): δ = 165.9, 165.1, 159.2, 159.2, 159.9, 154.1, 152.6, 151.1, 150.1, 149.4, 146. 1, 145.9, 145.3, 144.2, 142.0, 136.9, 136.8, 136.0, 135.8, 135.0, 132.7, 132.6, 130.9, 130.8, 130.5, 128.6, 127.1, 127.0, 124.0, 123.4, 121.6, 121.5, 117.8, 117.6, 115.4, 114.6, 113.6, 113.5, 111.7, 86.9, 86.8, 86.0, 85.4, 82.5, 82.3, 64.9, 63.4, 63.2, 59.2, 59.1, 59.0, 58.8, 58.6, 55.0, 54.9, 54.9, 43.6, 43.6, 37.5, 37.2, 30.5, 30.2, 24.8, 24.8, 24.7, 20.2, 20.1, 20.1. 31P NMR (202 MHz, C6D6): δ = 149.20, 148.95, 148.84, 148.20 (0.30:0.33:0.20:0.17). HRMS (ESI): m/z [M + Na]+ calcd for C24H24N6O5: 1001.4093; found: 1001.4120. 9b: 2 diastereomers + 2 rotamers. 1H NMR: (400 MHz, C6D6): δ = 9.87 (m, 2 H), 8.94 (s, 1 H), 8.92 (s, 1 H), 8.85 (s, 1 H), 8.84 (s, 1 H), 8.60 (m, 2 H), 8.44 (s, 1 H), 8.42 (s, 1 H), 8.24 (s, 1 H), 8.21 (s, 1 H), 8.03 (m, 4 H), 7.92 (m, 4 H), 7.86 (m, 4 H), 7.69 (m, 12 H), 7.49-7.63 (m, 20 H), 7.40 (m, 12 H), 7.32 (m, 12 H), 7.22 (m, 10 H), 7.04-7.18 (m, 12 H), 6.97 (m, 2 H), 6.85 (m, 8 H), 6.77 (m, 10 H), 5.87-6.03 (m, 2 H), 5.17-5.34 (m, 2 H), 4.99-5.15 (m, 2 H), 4.54-4.66 (m, 2 H), 4.41 (m, 2 H), 3.88 (m, 4 H), 3.74 (m, 2 H), 3.57-3.66 (m, 10 H), 3.31 (m, 12 H), 3.30 (m, 12 H), 3.00-3.16 (m, 8 H), 2.28-2.62 (m, 4 H), 1.70-1.97 (m, 10 H), 1.01-1.10 (m, 48 H). 13C NMR (101 MHz, C6D6): δ = 159.2, 149.7, 141.1, 136.0, 135.9, 134.9, 132.6, 131.9, 130.8, 130.6, 129.0, 129.0, 128.7, 128.6, 127.9, 127.1, 127.0, 119.7, 117.6, 117.0, 116.3, 113.6, 113.5, 87.0, 86.8, 85.8, 59.2, 59.0, 58.0, 58.0 54.8, 45.4, 45.3, 43.7, 43.6, 24.8, 24.8, 24.7, 24.6, 23.7, 22.9, 22.8, 22.8, 22.8, 20.6, 20.1, 20.1, 19.5, 19.4. 31P NMR (202 MHz, C6D6): δ = 149.37, 149.11, 148.69, 148.38 (0.31:0.37:0.17:0.15). MS (FAB): m/z [M + H]+ calcd for C29H26N6O4: 1025.4480; found: 1025.4.
19 Böge, N.; Gräsl, S.; Meier, C. J. Org. Chem. 2006, submitted.
20 Enzyme degradation: Oligonucleotide (3 µg) was dissolved in a NaOAc buffer (100 µL, pH 5.3, 30 mM). ZnSO4 solution (5 µL, 20 mM) and the nuclease P1 (3 units, from peni-cillium citrinum; Roche Nr. 91095923/30) were added and incubated for 4 h at 37 °C. Then a tris(hydroxy-methyl)aminomethane-HCl buffer (20 µL; pH 8.7; 50 mM) and 4 units of the alkaline phosphatase (Roche Nr. 49048126/15) were added and incubated overnight at 37 °C.
